Clinical trials: Uveal Melanoma With Liver Metastases, open to volunteers
Uveal Melanoma, Liver Metastases
PHP in Combination With IPI1/NIVO3 Compared to IPI3/NIVO1 Only in Patients With Uveal Melanoma Liver Metastases
Uveal melanoma is the most common primary intraocular malignancy in adults. Despite successful control of the primary tumor, metastatic disease will develop in approximately 35%-50% of the patients within 10 years.
- Trial name
- SCANDIUM-III (NCT06519266)
- Testing
- PHP, IPI1/NIVO3, IPI3/NIVO1
- Where
- 6 sites in Sweden
- Volunteers
- 40 people
- Sponsor
- Vastra Gotaland Region
Uveal Melanoma, Metastatic Cutaneous Melanoma
Locoregional Administration of TIL and Lymphodepletion in Patients With Melanoma and Liver Metastases
Evaluate the safety and tolerability of treatment with autologous tumor infiltrating lymphocytes (TIL) administered via hepatic arterial infusion and preconditioning with percutaneous hepatic perfusion in patients with liver…
- Trial name
- HAITILS-PHP (NCT05903937)
- Testing
- Autologous Tumor Infiltrating Lymphocytes, Melphalan, Interleukin-2
- Volunteers
- 6 people
- Sponsor
- Vastra Gotaland Region
Uveal Melanoma
Immune Response to Percutaneous Hepatic Perfusion With Melphalan for Ocular Melanoma Metastatic to the Liver
This study seeks to better understand the liver's immune response to receiving chemotherapy agent melphalan through Percutaneous Hepatic Perfusion (PHP) alone or in combination with Ipilimumab and Nivolumab for patients with…
- Trial name
- NCT07364474
- Testing
- Melphalan through Percutaneous Hepatic Perfusion, Melphalan through Percutaneous Hepatic Perfusion in combination with Ipilimumab and Nivolumab
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Massachusetts General Hospital